Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease
Identifieur interne : 000019 ( Istex/Corpus ); précédent : 000018; suivant : 000020Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease
Auteurs : Johannes Schiefer ; G. Bernhard Landwehrmeyer ; Hans-Gerd Lüesse ; Arne Sprünken ; Christiane Puls ; Anna Milkereit ; Eva Milkereit ; Christoph M. KosinskiSource :
- Movement Disorders [ 0885-3185 ] ; 2002-07.
English descriptors
- KwdEn :
Abstract
Glutamate excitotoxicity has been suggested to contribute to the pathogenesis of Huntington's disease (HD). Riluzole is a substance with glutamate antagonistic properties that is used for neuroprotective treatment in amyotrophic lateral sclerosis and which is currently tested in clinical trials for treatment of HD. R6/2 transgenic mice, which express exon 1 of the human HD gene with an expanded CAG triplet repeat, serve as a well‐characterized mouse model for HD with progressing neurological abnormalities and limited survival. We treated R6/2 HD transgenic mice with riluzole orally beginning at a presymptomatic stage until death to investigate its potential neuroprotective effects in this mouse model and found that survival time in the riluzole group was significantly increased in comparison to placebo‐treated transgenic controls. Additionally, the progressive weight loss was delayed and significantly reduced by riluzole treatment; behavioral testing of motor coordination and spontaneous locomotor activity, however, showed no statistically significant differences. We also examined the formation of the HD characteristic neuronal intranuclear inclusions (NII) immunohistologically. At a late disease stage, striatal NII from riluzole‐treated transgenic mice showed profound changes in ubiquitination, i.e., NII were less ubiquitinated and surrounded by ubiquitinated micro‐aggregates. Staining with antibodies directed against the mutated huntingtin revealed no significant difference in this component of NII. Taken together, these data suggest that riluzole is a promising candidate for neuroprotective treatment in human HD. © 2002 Movement Disorder Society
Url:
DOI: 10.1002/mds.10229
Links to Exploration step
ISTEX:1CC05411A34792F85059884719BD40FA39186252Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease</title><author><name sortKey="Schiefer, Johannes" sort="Schiefer, Johannes" uniqKey="Schiefer J" first="Johannes" last="Schiefer">Johannes Schiefer</name><affiliation><mods:affiliation>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Landwehrmeyer, G Bernhard" sort="Landwehrmeyer, G Bernhard" uniqKey="Landwehrmeyer G" first="G. Bernhard" last="Landwehrmeyer">G. Bernhard Landwehrmeyer</name><affiliation><mods:affiliation>University of Ulm, Department of Neurology, Ulm, Germany</mods:affiliation></affiliation></author><author><name sortKey="Luesse, Hans Erd" sort="Luesse, Hans Erd" uniqKey="Luesse H" first="Hans-Gerd" last="Lüesse">Hans-Gerd Lüesse</name><affiliation><mods:affiliation>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Sprunken, Arne" sort="Sprunken, Arne" uniqKey="Sprunken A" first="Arne" last="Sprünken">Arne Sprünken</name><affiliation><mods:affiliation>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Puls, Christiane" sort="Puls, Christiane" uniqKey="Puls C" first="Christiane" last="Puls">Christiane Puls</name><affiliation><mods:affiliation>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Milkereit, Anna" sort="Milkereit, Anna" uniqKey="Milkereit A" first="Anna" last="Milkereit">Anna Milkereit</name><affiliation><mods:affiliation>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Milkereit, Eva" sort="Milkereit, Eva" uniqKey="Milkereit E" first="Eva" last="Milkereit">Eva Milkereit</name><affiliation><mods:affiliation>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Kosinski, Christoph M" sort="Kosinski, Christoph M" uniqKey="Kosinski C" first="Christoph M." last="Kosinski">Christoph M. Kosinski</name><affiliation><mods:affiliation>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1CC05411A34792F85059884719BD40FA39186252</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1002/mds.10229</idno><idno type="url">https://api.istex.fr/document/1CC05411A34792F85059884719BD40FA39186252/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000019</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease</title><author><name sortKey="Schiefer, Johannes" sort="Schiefer, Johannes" uniqKey="Schiefer J" first="Johannes" last="Schiefer">Johannes Schiefer</name><affiliation><mods:affiliation>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Landwehrmeyer, G Bernhard" sort="Landwehrmeyer, G Bernhard" uniqKey="Landwehrmeyer G" first="G. Bernhard" last="Landwehrmeyer">G. Bernhard Landwehrmeyer</name><affiliation><mods:affiliation>University of Ulm, Department of Neurology, Ulm, Germany</mods:affiliation></affiliation></author><author><name sortKey="Luesse, Hans Erd" sort="Luesse, Hans Erd" uniqKey="Luesse H" first="Hans-Gerd" last="Lüesse">Hans-Gerd Lüesse</name><affiliation><mods:affiliation>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Sprunken, Arne" sort="Sprunken, Arne" uniqKey="Sprunken A" first="Arne" last="Sprünken">Arne Sprünken</name><affiliation><mods:affiliation>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Puls, Christiane" sort="Puls, Christiane" uniqKey="Puls C" first="Christiane" last="Puls">Christiane Puls</name><affiliation><mods:affiliation>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Milkereit, Anna" sort="Milkereit, Anna" uniqKey="Milkereit A" first="Anna" last="Milkereit">Anna Milkereit</name><affiliation><mods:affiliation>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Milkereit, Eva" sort="Milkereit, Eva" uniqKey="Milkereit E" first="Eva" last="Milkereit">Eva Milkereit</name><affiliation><mods:affiliation>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</mods:affiliation></affiliation></author><author><name sortKey="Kosinski, Christoph M" sort="Kosinski, Christoph M" uniqKey="Kosinski C" first="Christoph M." last="Kosinski">Christoph M. Kosinski</name><affiliation><mods:affiliation>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2002-07">2002-07</date><biblScope unit="vol">17</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="748">748</biblScope><biblScope unit="page" to="757">757</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">1CC05411A34792F85059884719BD40FA39186252</idno><idno type="DOI">10.1002/mds.10229</idno><idno type="ArticleID">MDS10229</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>excitotoxicity</term><term>glutamate antagonism</term><term>neurodegenerative disease</term><term>neuroprotection</term><term>polyglutamine disease</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Glutamate excitotoxicity has been suggested to contribute to the pathogenesis of Huntington's disease (HD). Riluzole is a substance with glutamate antagonistic properties that is used for neuroprotective treatment in amyotrophic lateral sclerosis and which is currently tested in clinical trials for treatment of HD. R6/2 transgenic mice, which express exon 1 of the human HD gene with an expanded CAG triplet repeat, serve as a well‐characterized mouse model for HD with progressing neurological abnormalities and limited survival. We treated R6/2 HD transgenic mice with riluzole orally beginning at a presymptomatic stage until death to investigate its potential neuroprotective effects in this mouse model and found that survival time in the riluzole group was significantly increased in comparison to placebo‐treated transgenic controls. Additionally, the progressive weight loss was delayed and significantly reduced by riluzole treatment; behavioral testing of motor coordination and spontaneous locomotor activity, however, showed no statistically significant differences. We also examined the formation of the HD characteristic neuronal intranuclear inclusions (NII) immunohistologically. At a late disease stage, striatal NII from riluzole‐treated transgenic mice showed profound changes in ubiquitination, i.e., NII were less ubiquitinated and surrounded by ubiquitinated micro‐aggregates. Staining with antibodies directed against the mutated huntingtin revealed no significant difference in this component of NII. Taken together, these data suggest that riluzole is a promising candidate for neuroprotective treatment in human HD. © 2002 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Johannes Schiefer MD</name><affiliations><json:string>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</json:string></affiliations></json:item><json:item><name>G. Bernhard Landwehrmeyer MD</name><affiliations><json:string>University of Ulm, Department of Neurology, Ulm, Germany</json:string></affiliations></json:item><json:item><name>Hans‐Gerd Lüesse</name><affiliations><json:string>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</json:string></affiliations></json:item><json:item><name>Arne Sprünken</name><affiliations><json:string>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</json:string></affiliations></json:item><json:item><name>Christiane Puls</name><affiliations><json:string>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</json:string></affiliations></json:item><json:item><name>Anna Milkereit</name><affiliations><json:string>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</json:string></affiliations></json:item><json:item><name>Eva Milkereit</name><affiliations><json:string>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</json:string></affiliations></json:item><json:item><name>Christoph M. Kosinski MD</name><affiliations><json:string>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>glutamate antagonism</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>excitotoxicity</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>neuroprotection</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>polyglutamine disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>neurodegenerative disease</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Glutamate excitotoxicity has been suggested to contribute to the pathogenesis of Huntington's disease (HD). Riluzole is a substance with glutamate antagonistic properties that is used for neuroprotective treatment in amyotrophic lateral sclerosis and which is currently tested in clinical trials for treatment of HD. R6/2 transgenic mice, which express exon 1 of the human HD gene with an expanded CAG triplet repeat, serve as a well‐characterized mouse model for HD with progressing neurological abnormalities and limited survival. We treated R6/2 HD transgenic mice with riluzole orally beginning at a presymptomatic stage until death to investigate its potential neuroprotective effects in this mouse model and found that survival time in the riluzole group was significantly increased in comparison to placebo‐treated transgenic controls. Additionally, the progressive weight loss was delayed and significantly reduced by riluzole treatment; behavioral testing of motor coordination and spontaneous locomotor activity, however, showed no statistically significant differences. We also examined the formation of the HD characteristic neuronal intranuclear inclusions (NII) immunohistologically. At a late disease stage, striatal NII from riluzole‐treated transgenic mice showed profound changes in ubiquitination, i.e., NII were less ubiquitinated and surrounded by ubiquitinated micro‐aggregates. Staining with antibodies directed against the mutated huntingtin revealed no significant difference in this component of NII. Taken together, these data suggest that riluzole is a promising candidate for neuroprotective treatment in human HD. © 2002 Movement Disorder Society</abstract><qualityIndicators><score>8.236</score><pdfVersion>1.4</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1676</abstractCharCount><pdfWordCount>5668</pdfWordCount><pdfCharCount>36208</pdfCharCount><pdfPageCount>10</pdfPageCount><abstractWordCount>228</abstractWordCount></qualityIndicators><title>Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease</title><genre><json:string>Serial article</json:string></genre><host><volume>17</volume><pages><total>10</total><last>757</last><first>748</first></pages><issn><json:string>0885-3185</json:string></issn><issue>4</issue><subject><json:item><value>Expedited Publication</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2002</publicationDate><copyrightDate>2002</copyrightDate><doi><json:string>10.1002/mds.10229</json:string></doi><id>1CC05411A34792F85059884719BD40FA39186252</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/1CC05411A34792F85059884719BD40FA39186252/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/1CC05411A34792F85059884719BD40FA39186252/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/1CC05411A34792F85059884719BD40FA39186252/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2002</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease</title><author><persName><forename type="first">Johannes</forename><surname>Schiefer</surname><roleName type="degree">MD</roleName></persName><affiliation>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</affiliation></author><author><persName><forename type="first">G. Bernhard</forename><surname>Landwehrmeyer</surname><roleName type="degree">MD</roleName></persName><affiliation>University of Ulm, Department of Neurology, Ulm, Germany</affiliation></author><author><persName><forename type="first">Hans‐Gerd</forename><surname>Lüesse</surname></persName><affiliation>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</affiliation></author><author><persName><forename type="first">Arne</forename><surname>Sprünken</surname></persName><affiliation>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</affiliation></author><author><persName><forename type="first">Christiane</forename><surname>Puls</surname></persName><affiliation>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</affiliation></author><author><persName><forename type="first">Anna</forename><surname>Milkereit</surname></persName><affiliation>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</affiliation></author><author><persName><forename type="first">Eva</forename><surname>Milkereit</surname></persName><affiliation>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</affiliation></author><author><persName><forename type="first">Christoph M.</forename><surname>Kosinski</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: Department of Neurology, University Hospital RWTH Aachen, Pauwelsstrasse 30, D‐52057 Aachen, Germany</p></note><affiliation>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2002-07"></date><biblScope unit="vol">17</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="748">748</biblScope><biblScope unit="page" to="757">757</biblScope></imprint></monogr><idno type="istex">1CC05411A34792F85059884719BD40FA39186252</idno><idno type="DOI">10.1002/mds.10229</idno><idno type="ArticleID">MDS10229</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2002</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Glutamate excitotoxicity has been suggested to contribute to the pathogenesis of Huntington's disease (HD). Riluzole is a substance with glutamate antagonistic properties that is used for neuroprotective treatment in amyotrophic lateral sclerosis and which is currently tested in clinical trials for treatment of HD. R6/2 transgenic mice, which express exon 1 of the human HD gene with an expanded CAG triplet repeat, serve as a well‐characterized mouse model for HD with progressing neurological abnormalities and limited survival. We treated R6/2 HD transgenic mice with riluzole orally beginning at a presymptomatic stage until death to investigate its potential neuroprotective effects in this mouse model and found that survival time in the riluzole group was significantly increased in comparison to placebo‐treated transgenic controls. Additionally, the progressive weight loss was delayed and significantly reduced by riluzole treatment; behavioral testing of motor coordination and spontaneous locomotor activity, however, showed no statistically significant differences. We also examined the formation of the HD characteristic neuronal intranuclear inclusions (NII) immunohistologically. At a late disease stage, striatal NII from riluzole‐treated transgenic mice showed profound changes in ubiquitination, i.e., NII were less ubiquitinated and surrounded by ubiquitinated micro‐aggregates. Staining with antibodies directed against the mutated huntingtin revealed no significant difference in this component of NII. Taken together, these data suggest that riluzole is a promising candidate for neuroprotective treatment in human HD. © 2002 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>glutamate antagonism</term></item><item><term>excitotoxicity</term></item><item><term>neuroprotection</term></item><item><term>polyglutamine disease</term></item><item><term>neurodegenerative disease</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Expedited Publication</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2001-11-02">Received</change><change when="2002-02-20">Registration</change><change when="2002-07">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/1CC05411A34792F85059884719BD40FA39186252/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>New York</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="40"><doi origin="wiley" registered="yes">10.1002/mds.v17:4</doi><numberingGroup><numbering type="journalVolume" number="17">17</numbering><numbering type="journalIssue">4</numbering></numberingGroup><coverDate startDate="2002-07">July/August 2002</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="210" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.10229</doi><idGroup><id type="unit" value="MDS10229"></id></idGroup><countGroup><count type="pageTotal" number="10"></count></countGroup><titleGroup><title type="articleCategory">Expedited Publication</title><title type="tocHeading1">Expedited Publication</title></titleGroup><copyright ownership="thirdParty">Copyright © 2002 Movement Disorders Society</copyright><eventGroup><event type="manuscriptReceived" date="2001-11-02"></event><event type="manuscriptRevised" date="2002-02-09"></event><event type="manuscriptAccepted" date="2002-02-20"></event><event type="firstOnline" date="2002-04-17"></event><event type="publishedOnlineFinalForm" date="2002-07-22"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2002-04-17"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">748</numbering><numbering type="pageLast">757</numbering></numberingGroup><correspondenceTo>Department of Neurology, University Hospital RWTH Aachen, Pauwelsstrasse 30, D‐52057 Aachen, Germany</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS10229.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="3"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="41"></count><count type="wordTotal" number="5464"></count></countGroup><titleGroup><title type="main" xml:lang="en">Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease</title><title type="short" xml:lang="en">Riluzole is Neuroprotective in HD Transgenic Mice</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Johannes</givenNames><familyName>Schiefer</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>G. Bernhard</givenNames><familyName>Landwehrmeyer</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Hans‐Gerd</givenNames><familyName>Lüesse</familyName></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Arne</givenNames><familyName>Sprünken</familyName></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Christiane</givenNames><familyName>Puls</familyName></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Anna</givenNames><familyName>Milkereit</familyName></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Eva</givenNames><familyName>Milkereit</familyName></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Christoph M.</givenNames><familyName>Kosinski</familyName><degrees>MD</degrees></personName><contactDetails><email normalForm="christoph.kosinski@post.rwth-aachen.de">christoph.kosinski@post.rwth‐aachen.de</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="DE" type="organization"><unparsedAffiliation>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="DE" type="organization"><unparsedAffiliation>University of Ulm, Department of Neurology, Ulm, Germany</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">glutamate antagonism</keyword><keyword xml:id="kwd2">excitotoxicity</keyword><keyword xml:id="kwd3">neuroprotection</keyword><keyword xml:id="kwd4">polyglutamine disease</keyword><keyword xml:id="kwd5">neurodegenerative disease</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Glutamate excitotoxicity has been suggested to contribute to the pathogenesis of Huntington's disease (HD). Riluzole is a substance with glutamate antagonistic properties that is used for neuroprotective treatment in amyotrophic lateral sclerosis and which is currently tested in clinical trials for treatment of HD. R6/2 transgenic mice, which express exon 1 of the human HD gene with an expanded CAG triplet repeat, serve as a well‐characterized mouse model for HD with progressing neurological abnormalities and limited survival. We treated R6/2 HD transgenic mice with riluzole orally beginning at a presymptomatic stage until death to investigate its potential neuroprotective effects in this mouse model and found that survival time in the riluzole group was significantly increased in comparison to placebo‐treated transgenic controls. Additionally, the progressive weight loss was delayed and significantly reduced by riluzole treatment; behavioral testing of motor coordination and spontaneous locomotor activity, however, showed no statistically significant differences. We also examined the formation of the HD characteristic neuronal intranuclear inclusions (NII) immunohistologically. At a late disease stage, striatal NII from riluzole‐treated transgenic mice showed profound changes in ubiquitination, i.e., NII were less ubiquitinated and surrounded by ubiquitinated micro‐aggregates. Staining with antibodies directed against the mutated huntingtin revealed no significant difference in this component of NII. Taken together, these data suggest that riluzole is a promising candidate for neuroprotective treatment in human HD. © 2002 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 4-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Riluzole is Neuroprotective in HD Transgenic Mice</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease</title></titleInfo><name type="personal"><namePart type="given">Johannes</namePart><namePart type="family">Schiefer</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G. Bernhard</namePart><namePart type="family">Landwehrmeyer</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>University of Ulm, Department of Neurology, Ulm, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Hans‐Gerd</namePart><namePart type="family">Lüesse</namePart><affiliation>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Arne</namePart><namePart type="family">Sprünken</namePart><affiliation>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christiane</namePart><namePart type="family">Puls</namePart><affiliation>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anna</namePart><namePart type="family">Milkereit</namePart><affiliation>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Eva</namePart><namePart type="family">Milkereit</namePart><affiliation>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christoph M.</namePart><namePart type="family">Kosinski</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>University Hospital RWTH Aachen, Department of Neurology, Aachen, Germany</affiliation><description>Correspondence: Department of Neurology, University Hospital RWTH Aachen, Pauwelsstrasse 30, D‐52057 Aachen, Germany</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">New York</placeTerm></place><dateIssued encoding="w3cdtf">2002-07</dateIssued><dateCaptured encoding="w3cdtf">2001-11-02</dateCaptured><dateValid encoding="w3cdtf">2002-02-20</dateValid><copyrightDate encoding="w3cdtf">2002</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">3</extent><extent unit="tables">1</extent><extent unit="references">41</extent><extent unit="words">5464</extent></physicalDescription><abstract lang="en">Glutamate excitotoxicity has been suggested to contribute to the pathogenesis of Huntington's disease (HD). Riluzole is a substance with glutamate antagonistic properties that is used for neuroprotective treatment in amyotrophic lateral sclerosis and which is currently tested in clinical trials for treatment of HD. R6/2 transgenic mice, which express exon 1 of the human HD gene with an expanded CAG triplet repeat, serve as a well‐characterized mouse model for HD with progressing neurological abnormalities and limited survival. We treated R6/2 HD transgenic mice with riluzole orally beginning at a presymptomatic stage until death to investigate its potential neuroprotective effects in this mouse model and found that survival time in the riluzole group was significantly increased in comparison to placebo‐treated transgenic controls. Additionally, the progressive weight loss was delayed and significantly reduced by riluzole treatment; behavioral testing of motor coordination and spontaneous locomotor activity, however, showed no statistically significant differences. We also examined the formation of the HD characteristic neuronal intranuclear inclusions (NII) immunohistologically. At a late disease stage, striatal NII from riluzole‐treated transgenic mice showed profound changes in ubiquitination, i.e., NII were less ubiquitinated and surrounded by ubiquitinated micro‐aggregates. Staining with antibodies directed against the mutated huntingtin revealed no significant difference in this component of NII. Taken together, these data suggest that riluzole is a promising candidate for neuroprotective treatment in human HD. © 2002 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>glutamate antagonism</topic><topic>excitotoxicity</topic><topic>neuroprotection</topic><topic>polyglutamine disease</topic><topic>neurodegenerative disease</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Expedited Publication</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>748</start><end>757</end><total>10</total></extent></part></relatedItem><identifier type="istex">1CC05411A34792F85059884719BD40FA39186252</identifier><identifier type="DOI">10.1002/mds.10229</identifier><identifier type="ArticleID">MDS10229</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2002 Movement Disorders Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000019 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000019 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:1CC05411A34792F85059884719BD40FA39186252
|texte= Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease
}}
| This area was generated with Dilib version V0.6.23. |  |